- Home
- SSTI vs PLX Comparison
SSTI vs PLX Comparison
Compare SSTI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- PLX
- Stock Information
- Founded
- SSTI 1996
- PLX 1993
- Country
- SSTI United States
- PLX United States
- Employees
- SSTI N/A
- PLX N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSTI Technology
- PLX Health Care
- Exchange
- SSTI Nasdaq
- PLX Nasdaq
- Market Cap
- SSTI 189.1M
- PLX 160.2M
- IPO Year
- SSTI 2017
- PLX 1998
- Fundamental
- Price
- SSTI $15.51
- PLX $1.55
- Analyst Decision
- SSTI Buy
- PLX Strong Buy
- Analyst Count
- SSTI 8
- PLX 1
- Target Price
- SSTI $20.38
- PLX $15.00
- AVG Volume (30 Days)
- SSTI 46.0K
- PLX 1.4M
- Earning Date
- SSTI 05-13-2025
- PLX 05-09-2025
- Dividend Yield
- SSTI N/A
- PLX N/A
- EPS Growth
- SSTI N/A
- PLX N/A
- EPS
- SSTI N/A
- PLX 0.05
- Revenue
- SSTI $104,970,000.00
- PLX $59,764,000.00
- Revenue This Year
- SSTI $11.44
- PLX $65.02
- Revenue Next Year
- SSTI $8.36
- PLX $57.34
- P/E Ratio
- SSTI N/A
- PLX $32.18
- Revenue Growth
- SSTI 7.65
- PLX 0.18
- 52 Week Low
- SSTI $9.33
- PLX $0.82
- 52 Week High
- SSTI $19.43
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SSTI 51.26
- PLX 30.03
- Support Level
- SSTI $14.34
- PLX $1.54
- Resistance Level
- SSTI $15.70
- PLX $1.79
- Average True Range (ATR)
- SSTI 1.01
- PLX 0.11
- MACD
- SSTI 0.05
- PLX -0.02
- Stochastic Oscillator
- SSTI 43.21
- PLX 27.27
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.